Drug Profile

Research programme: anti-cancer antibody therapeutics - STCube Pharmaceuticals

Latest Information Update: 28 Aug 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator STCube Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
Developer STCube Pharmaceuticals
Class Antibodies; Antineoplastics; Immunotherapies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Cancer

28 Aug 2022 No recent reports of development identified for research development in Cancer in South Korea (Parenteral)
31 Jul 2018 Research programme: anti-cancer antibody therapeutics - STCube Pharmaceuticals is available for licensing as of 31 Jul 2018 (STCube Pharmaceuticals pipeline, July 2018)
31 Jul 2018 Early research in Cancer in South Korea (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com